Efficacy and safety of rechallenge with [ 177 Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer.

Giulia SantoGianpaolo Di SantoAnna SviridenkoSteffen BayerschmidtLukas WirthFabian ScherbauerPeter LehmannElisabeth von GuggenbergClemens DecristoforoIsabel Heidegger-PircherJasmin BekticIrene J Virgolini

Published in: European journal of nuclear medicine and molecular imaging (2024)

More than half of patients benefit from rechallenge PRLT. Our analysis suggests that rechallenge may prolong survival in selected patients, with an acceptable safety profile.

Keyphrases

ejection fraction
newly diagnosed
small cell lung cancer
squamous cell carcinoma
prognostic factors
computed tomography
stem cells
pet imaging
mesenchymal stem cells
patient reported
chemotherapy induced